Novartis Receives EU Approval for Gene Therapy Luxturna (voretigene neparvovec) in Patients with Rare Inherited Retinal Disease

 Novartis Receives EU Approval for Gene Therapy Luxturna (voretigene neparvovec) in Patients with Rare Inherited Retinal Disease

Novartis Receives EU Approval for Gene Therapy Luxturna (voretigene neparvovec) in Patients with Rare Inherited Retinal Disease

Shots:

  • The approval is based on P-III trial, involving assesment of Luxturna vs control group patients, with inherited retinal disease (caused due to mutation in both copies of the RPE65 gene and sufficient viable retinal cells)
  • Results: Vision improvement recorded @ 30 days following treatment, @1yr. MLMT (multi-luminance mobility test) (1.6); 65% patients successfully navigate the MLMT at the lowest light level of 1 lux
  • Luxturna is gene therapy to restore vision is designed to provide a working copy of the RPE65 gene to act in place of the mutated RPE65 gene and currently marketed by Spark Therapeutics in the US

Click here to read full press release/ article | Ref: Novartis | Image: Pharmaceutical Technology

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post